Here's what the science actually says, in one sentence: sickle cell and beta-thalassemia are diseases of a broken adult hemoglobin gene, and the CRISPR fix doesn't repair that gene directly — it reawakens a backup gene the body switches off after birth.
Everyone is born making fetal hemoglobin, a version of the oxygen-carrying protein that works fine. Shortly after birth the body flips a switch and makes adult hemoglobin instead. In these diseases, the adult version is the broken one. So the clever move is to flip the switch back — reactivate the fetal gene and let it pick up the slack.
The patent record shows exactly that mechanism being claimed. Publication US20230310506A1 covers a method for activating expression of the gamma-globin gene — gamma-globin being the fetal-hemoglobin component. That is the switch.
But reactivating a gene is only useful if you can do it in the right cells and turn them into a treatment. Stanford's grant US11634732B2 covers pharmaceutical compositions comprising gene-corrected primary cells — in plain terms, the corrected blood stem cells formulated as a medicine. Sangamo's US11845965B2 covers regulating gene expression using engineered nucleases for exactly these blood disorders.
And the manufacturing reality shows up too. CSL Behring Gene Therapy's US11795461B2 covers compositions and methods for treating beta-hemoglobinopathies — the umbrella term for this disease family. Same target, multiple owners, each claiming a slice.
So the crosswalk is this: one disease mechanism (a broken adult hemoglobin gene), one elegant workaround (reawaken the fetal gene), and a patent record that splits the work into reactivation, cell correction, and the finished medicine. Reading them together is how you see why the first approved CRISPR therapy looks the way it does.